Ultragenyx Pharmaceutical is reducing its workforce by 10%, or approximately 130 employees, as part of a strategic restructuring to lower cash burn and work toward profitability in 2027. The cuts follow the Phase 3 failure of its investigational antibody setrusumab for osteogenesis imperfecta.
